p53 and K-ras gene mutations correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer

Citation
S. Tortola et al., p53 and K-ras gene mutations correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer, J CL ONCOL, 17(5), 1999, pp. 1375-1381
Citations number
33
Categorie Soggetti
Oncology,"Onconogenesis & Cancer Research
Journal title
JOURNAL OF CLINICAL ONCOLOGY
ISSN journal
0732183X → ACNP
Volume
17
Issue
5
Year of publication
1999
Pages
1375 - 1381
Database
ISI
SICI code
0732-183X(199905)17:5<1375:PAKGMC>2.0.ZU;2-M
Abstract
Purpose: p53 gene and K-ras mutations are among the most common genetic alt erations present in colorectal cancer. The prognostic utility of such mutat ions remains controversial. The purpose of this study was to prospectively evaluate the prognostic significance of p53 and K-ras gene mutations in col orectal cancer. Patients and Methods: One hundred forty patients were analyzed. Tumors belo nging to the microsatellite mutator phenotype were excluded (n = 8). Mutati ons at the K-ras and p53 genes were detected and characterized by restricti on fragment length polymorphism, single-strand conformation polymorphism, a nd sequencing, as appropriate. Results: p53 mutations were detected in 66 (50%) and K-ras mutations were d etected in 54 (41%) of the 132 patients. In 26 cases (20%), ras and p53 mut ations coexisted; in 38 cases (29%), neither mutation was found. Multivaria te analysis of the whole population analyzed (n = 132) showed that survival was strongly correlated with the presence of p53 mutations alone or in com bination with K-ros mutations (P =.002; log-rank test). When only patients undergoing a radical resection were considered (R0; n = 101), p53 mutations were no longer of prognostic significance. Conclusion: p53 mutations alone or in combination with K-ras mutations are correlated with a worse outcome. However, the routine use of these mutation s as prognostic markers in the clinical setting is not recommended. J Clin Oncol 17:1375-1381. (C) 1999 by American Society of Clinical Oncology.